Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05647265 · ClinicalTrials.gov registry record · Phase 2
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
A Phase 2 study of Pleural Biphasic Mesothelioma and Pleural Sarcomatoid Mesothelioma, sponsored by Alliance for Clinical Trials in Oncology.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 20
- Study locations
NCT05647265 is a Phase 2 study of Pleural Biphasic Mesothelioma and Pleural Sarcomatoid Mesothelioma that is actively recruiting participants, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 26 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT05647265, a Phase 2 study of Pleural Biphasic Mesothelioma and Pleural Sarcomatoid Mesothelioma, is actively recruiting participants, sponsored by Alliance for Clinical Trials in Oncology.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving immunotherapy before surgery may be more effective at controlling disease in patients with sarcomatoid mesothelioma than giving immunotherapy alone.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- BIOLOGICAL Nivolumab
- PROCEDURE Surgical Procedure
- BIOLOGICAL Ipilimumab
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
California
- PCR Oncology - Arroyo Grande
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
- UC San Diego Moores Cancer Center - La Jolla
- Providence Queen of The Valley - Napa
- Providence Medical Foundation - Santa Rosa - Santa Rosa
- Providence Santa Rosa Memorial Hospital - Santa Rosa
Delaware
- Beebe Medical Center - Lewes
- Beebe South Coastal Health Campus - Millville
- Delaware Clinical and Laboratory Physicians PA - Newark
- Helen F Graham Cancer Center - Newark
Arizona
- Kingman Regional Medical Center - Kingman
- Mayo Clinic Hospital in Arizona - Phoenix
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2024-11-27 |
| Est. Completion | 2026-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05647265
The ClinicalTrials.gov registry entry for NCT05647265 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pleural Biphasic Mesothelioma appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.
NCT05647265 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Alaska, California, Delaware.
Frequently Asked Questions
What is clinical trial NCT05647265 about?
NCT05647265 is a clinical study titled "Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma". This phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's...
What is the current status of trial NCT05647265?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2024-11-27. Estimated completion is 2026-12-15.
What conditions does trial NCT05647265 study?
This clinical trial studies the following conditions: Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma.
What interventions are being tested in trial NCT05647265?
The interventions under investigation include: Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Nivolumab (BIOLOGICAL), Surgical Procedure (PROCEDURE), Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05647265?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05647265 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pleural Biphasic Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.